Concorde Asset Management’s Anixa Biosciences ANIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $37.6K | Hold |
13,969
| – | – | 0.02% | 175 |
|
|
2024
Q4 | $32.4K | Hold |
13,969
| – | – | 0.02% | 182 |
|
|
2024
Q3 | $44K | Hold |
13,969
| – | – | 0.02% | 175 |
|
|
2024
Q2 | $30.9K | Buy |
+13,969
| New | +$30.9K | 0.02% | 162 |
|
|
2024
Q1 | – | Sell |
-15,459
| Closed | -$60K | – | 139 |
|
|
2023
Q4 | $60K | Hold |
15,459
| – | – | 0.04% | 160 |
|
|
2023
Q3 | $50.6K | Sell |
15,459
-22
| -0.1% | -$72 | 0.05% | 141 |
|
|
2023
Q2 | $49.5K | Buy |
+15,481
| New | +$49.5K | 0.05% | 128 |
|
|
2023
Q1 | – | Sell |
-15,500
| Closed | -$65.9K | – | 81 |
|
|
2022
Q4 | $65.9K | Sell |
15,500
-475
| -3% | -$2.02K | 0.06% | 141 |
|
|
2022
Q3 | $79K | Sell |
15,975
-25
| -0.2% | -$124 | 0.09% | 134 |
|
|
2022
Q2 | $49K | Hold |
16,000
| – | – | 0.07% | 106 |
|
|
2022
Q1 | $44K | Hold |
16,000
| – | – | 0.03% | 151 |
|
|
2021
Q4 | $48K | Buy |
16,000
+3,000
| +23% | +$9K | 0.03% | 168 |
|
|
2021
Q3 | $62K | Hold |
13,000
| – | – | 0.04% | 194 |
|
|
2021
Q2 | $50K | Hold |
13,000
| – | – | 0.03% | 194 |
|
|
2021
Q1 | $61K | Buy |
+13,000
| New | +$61K | 0.04% | 209 |
|
|
2018
Q3 | – | Sell |
-10,000
| Closed | -$30K | – | 144 |
|
|
2018
Q2 | $30K | Sell |
10,000
-1,520
| -13% | -$4.56K | 0.03% | 123 |
|
|
2018
Q1 | $53K | Hold |
11,520
| – | – | 0.06% | 115 |
|
|
2017
Q4 | $27K | Sell |
11,520
-2,000
| -15% | -$4.69K | 0.03% | 116 |
|
|
2017
Q3 | $36K | Buy |
+13,520
| New | +$36K | 0.03% | 151 |
|